Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference

References

• World Health Organization. Prevention and management of osteoporosis. World Health Organ Tech Rep Series 2003;921:1-164
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis (online). Available at: http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf. Accessed October 2011
   Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465-75
   PubMed Web of Science ®Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   PubMed Web of Science ®Google Scholar
• Quesada Gómez JM, Blanch Rubió J, Díaz Curiel M, et al. Calcium citrate and vitamin D in the treatment of osteoporosis. Clin Drug Investig 2011;31:285-98
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Downey TW, Foltz SH, Boccuzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006;99:570-5
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24
   PubMed Web of Science ®Google Scholar
• Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-8
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone 2005;37:651-4
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Skag A, Christiansen C, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. HORIZON Recurrent Fracture Trial. N Engl J Med 2007;357:1799-809
   PubMed Web of Science ®Google Scholar
• Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin 2008;24:107-19
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg MC, Bonnick SL, et al. Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51
   PubMed Web of Science ®Google Scholar
• Miller PD, Epstein S, Sedarati F, et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13
   PubMed Web of Science ®Google Scholar
• Pazianas, M, Epstein S, Zaidi M. Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials 2009;4:122-30
   PubMedGoogle Scholar
• Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114-20
   PubMed Web of Science ®Google Scholar
• Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 2004;10:142-51
   PubMedGoogle Scholar
• Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34
   PubMed Web of Science ®Google Scholar
• Cadarette SM, Katz JN, Brookhart MA, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008;148:637-46
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 2009;20:973-8
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259-69
   PubMed Web of Science ®Google Scholar
• Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
   PubMed Web of Science ®Google Scholar
• Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631-8
   PubMed Web of Science ®Google Scholar
• Actonel® (risedronate sodium) tablets. Prescribing information, February 2011. Warner Chilcott Pharmaceuticals Inc., Mason, OH, USA. Available at: http://www.actonel.com/global/prescribing_information.pdf. Accessed October 2011
   Google Scholar
• Boniva® (ibandronate sodium) tablets. Prescribing information, January 2011. Genentech Inc., USA. A member of the Roche group, South San Francisco, CA, USA. Available at: http://www.gene.com/gene/products/information/boniva/pdf/pi.pdf. Accessed October 2011
   Google Scholar
• Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011;1218:38-46
   PubMed Web of Science ®Google Scholar
• Pazianas M, Cooper C, Ebetino FH, et al. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325-43
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Äkesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22:373-90
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-9
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Emkey RD, Ettinger MP. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119(4 Suppl 1):18-24S
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Gallagher R, MacCosbe PE, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Endocr Pract 2006;12:522-8
   PubMedGoogle Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-19
   PubMed Web of Science ®Google Scholar
• Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic [abstract]. J Bone Miner Res 2001;15(Suppl 1): Abstract M406
   Google Scholar
• Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38(4 Suppl 1):S-S6
   Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
   PubMed Web of Science ®Google Scholar
• Gold DT, Martin BC, Frytak JR, et al. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007;23:585-94
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, et al. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007;18:271-7
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
   PubMed Web of Science ®Google Scholar
• Keen R, Jodar E, Iolascon G, et al. European women’s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 2006;22:2375-81
   PubMed Web of Science ®Google Scholar
• Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 2006;22:949-60
   PubMed Web of Science ®Google Scholar
• Weiss TX, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect 2007;10:211-23
   PubMed Web of Science ®Google Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
   PubMed Web of Science ®Google Scholar
• Walliser JA, Bolge SC, Sen SS. Patients' preference for osteoporosis medications: PREFER-International. International Society for Clinical Densitometry Annual Meeting, 1–4 February 2006, San Diego, CA, USA, 2006;B-57:Abstract 213
   Google Scholar
• Gold DT, Silverman SL. Compliance and persistence with osteoporosis therapies: we can do better. Future Rheumatol 2007;2:443-5
   Google Scholar
• Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
   PubMed Web of Science ®Google Scholar
• Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;94:1296-304
   Google Scholar
• Briesacher BA, Andrade SE, Harrold LR, et al. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 2010;123:275-80
   PubMed Web of Science ®Google Scholar
• Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2011;22:741-53
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2011;doi:10.1007/s00198-011-1535-z
   Google Scholar
• Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007;24:37-55
   PubMed Web of Science ®Google Scholar